File No. CT/05/23-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/23/000005

To,

M/s IQVIA RDS (India) Private Limited,
Omega Embassy TechSquare Marathahalli-Sarjapur,
Outer Ring Road Kadubeesanahalli Bangalore (India) – 560103.

Sir,

With reference to your application No. GCT/CT04/FF/2023/35559 (GCT/05/23) dated 04-01-2023, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis" Protocol No.: ABX464-106, Version 3.0 Dated 06/October/2022 with a total of up-to 40 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial;

(xviii) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xix) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769041015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=657F5E47D940985D8F03BDC902D0E1FE73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.05.12 10:14:39 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

File No. CT/05/23-DCG(I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s IQVIA RDS (India) Private Limited, Omega Embassy TechSquare, Marathahalli - Sarjapur Outer Ring Road Kadubeesanahalli Bangalore (India) – 560103** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: ABX464-106, Version 3.0 Dated 06/October/2022** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769
postalCode=110002, st=DELHI, serialNumber=657F5E47D940985D8F03BDC902D0E1FEC3CFA1
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.05.12 10:14:49 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority

Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	ABX464 (Obefazimod)
Therapeutic class:	Anti-inflammatory
Dosage form:	Capsules
Composition:	Cellulose, microcrystalline= 165.0000 milligram (mg)U.S.P.,E.P.,J.P. Inactive ABX464 = 25.0000 milligram (mg) In House Specification Active Povidone K30 =20.0000 milligram(mg) U.S.P.,E.P.,J.P. Inactive Povidone K30 = 20.0000 milligram(mg) J.P., Ph. Eur Inactive ABX464 = 50.0000 milligram (mg)In House Specification Active Cellulose, microcrystalline =140.0000 milligram (mg) U.S.P., J.P., Ph. Eur Inactive

Indications:	Moderately to severely active ulcerative colitis

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Fortis Escorts Heart Institute Okhla Road, New Delhi - 110025	Institutional Ethics Committee, Academic and Research Department, Room no.23, 2nd Floor, Residential Tower, Okhla Road, New Delhi-110025 ECR/261/Inst/DL/2013/RR-19	Dr. Pankaj Puri
2.	Department of Gastroenterology, Maharaja Agrasen Hospital, West Punjabi Bagh, New Delhi-110026	Institutional Ethics Committee, Maharaja Agrasen Hospital, West Punjabi Bagh, New Delhi-110026 ECR/745/Inst/DL/2015/RR-21	Dr. Vivek Bhatia
3.	SIDS Hospital and Research Centre, A unit of SIDS Healthcare Pvt. Ltd., JJ Empire and Tapi villa Building, Vijaynagar Gate no. 3, Opposite Gandhi Engineering College, Majura Gate, Ring Road, Surat-395002, Gujarat, India	Surat Institute of Digestive Sciences Ethics Committee, Surat Institute of Digestive Sciences, SIDS Hospital and Research Centre, A unit of SIDS Healthcare Pvt. Ltd., Vijaynagar Gate no. 3, Besides Nirman Bhavan, Opposite Gandhi Engineering College, Majura Gate, Ring Road, Surat-395002, Gujarat, India ECR/813/Inst/GJ/2016/RR-19	Dr. Mehta Rajiv Manhar
4.	School of Digestive and Liver Disease, Dept. of Gastroenterology, 4th Floor, Ronald Ross Bldg, IPGME&R / SSKM Hospital, 244, AJC Bose Road, Kolkata-700020, West Bengal, India	IPGME and R Research Oversight Committee, IPGME and R, 244, Acharya JC Bose Road, Kolkata-700020, West Bengal, India ECR/35/Inst/WB/2013/RR-19	Dr. Rajib Sarkar

5.	Acharya Vinoba Bhave Rural Hospital, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (W), Wardha-442004, Maharashtra, India	Institutional Ethics Committee Datta Meghe Institute of Medical Sciences, Research House, Near Food Court, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi-442004, Maharashtra, India ECR/440/Inst/MH/2013/RR-19	Dr. Kirnake Vijendra Vasantrao
6.	SRM Institutes for Medical Science (SIMS), No. 1 Jawaharlal Nehru Salai, Vadapalani, Chennai-600026	Institutional Ethics Committee SRM Institutes for Medical Science (SIMS), No. 1 Jawaharlal Nehru Salai, Vadapalani, Chennai-600026, Tamil Nadu, India ECR/805/Inst/TN/2016/RR-22	Dr. Siddartha Ramakrishna Balakrishnan
7.	All India Institute of Medical Sciences Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences Ansari Nagar, New Delhi-110029, India	Institute Ethics Committee, All India Institute of Medical Sciences, Room No.102, First Floor, Old O.T. Block, Ansari Nagar, New Delhi-110029, India ECR/538/Inst/DL/2014/RR-20	Dr. Vineet Ahuja
8.	Lakeshore Hospital And Research Centre Ltd, Lakeshore Hospital And Research Centre Ltd, XVI/6I2, Maradu, Nettoor PO, Koshi-682040	Lakeshore Ethics Committee, Lakeshore Hospital And Research Centre Ltd, XVI/6I2, Maradu, Nettoor PO, Koshi-682040 ECR/115/Inst/Ker/2013/RR-19	Dr. Abraham Koshy
9.	Vinaya Hospital and Research Centre (A Unit of Karnataka Institute of Medical Sciences), Karangalpady, Mangaluru-575003, Karnataka, India	Ethics Committee Vinaya Hospital, Vinaya Hospital and Research Centre, P.O. Box No. 717 Karangalpady, Mangaluru, 575003, Karnataka, India ECR/664/Inst/KA/2014/RR-20	Dr. Hamsraj Alva
10.	Yashoda Hospitals, Rajbhavanroad, Somajiguda, Hyderabad-500082, Telangana, India	Institutional Ethics Committee, Yashoda Academy of Medical Education and Research, Yashoda Group of Hospitals, Yashoda Hospital, Behind Hari Hara Kalabhavan, S.P. Road, Secunderabad-500003, Telangana	Dr. Kiran Kumar Peddi

		State ECR/49/Inst/AP/2013/RR-22	
11.	Lokmanya Tilak Municipal Medical College & General Hospital, Gastroenterology Department Dr. Babasaheb Ambedkar Road, Sion, West Mumbai-400022, India	Institutional Ethics Committee Lokmanya Tilak, Dr. Babasaheb Ambedkar Road, Sion, West Mumbai-400022, Maharashtra, India ECR/266/Lokmanya/Inst/MH/2013/RR-19	Dr. Meghraj Ingle
12.	PGIMER, SECTOR-12, Chandigarh-160012 India.	Institutional Ethics Committee, Room no 6006, 6th Floor Research block-B, PGIMER, Sector-12, Chandigarh-160012 India ECR/25/Inst/CH/2013/RR-20	Dr. Usha Dutta
13.	Gujarat Hospital-Gastro and Vascular Centre, Opposite Shree Ram Petrol Pump, Anand Mahal Road, Adajan, Surat, Gujarat-395009, India	Unity Hospital Ethics Committee, Unity Trauma Center and ICU, N-4 Janki Park Society, Aai Mata Road, Paravat Patiya, Surat, Gujarat-395010, India ECR/1226/Inst/GJ/2019	Dr Saumin Prakashbhai Shah
14.	MRC 12105, Inpatient Block, 5th floor, Department of Gastroenterology, Gandhi Hospital, Department, Musheerabad, Secunderabad-500003, Telangana, India	Institutional Ethics Committee, Gandhi Medical/Hospital College, Musheerabad, Secunderabad-500003, Telangana, India ECR/180/Inst/AP/2013/RR-19	Dr. P. Shravan Kumar
15.	Origin Hospital, A Unit of C.L.R.D, Sr. no. 2-5-36/CLRD/1, Chintalmet X road, Near Pillar No. 177, PVNR Expressway, Attapur, Hyderabad-500048, Telangana, India	Institutional Ethics Committee, Origin Hospital, 2-5-36/CLRD/1, Chintalmet X road, Rajendra Nagar (M), Ranga Reddy, Hyderabad-500048, Telangana, India ECR/1689/Inst/TG/2022	Dr. Mohd Aejaz Habeeb

16.	International Gastro Institute-Isha Hospital, 7th Floor, Isha Hospital, B/h, Atlantis, Sarabhai Road, Vadodara, Gujarat-390007, India	Ethics Committee Isha Hospital, Behind Atlantis, opp Vadodara central sarabhai campus, Subhanpura, Vadodara, Gujarat-390007, India ECR/1120/Inst/GJ/2018/RR-21	Dr. Ashishkumar Premnath Sethi

****